[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601908":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":11,"studyPopulation":11,"armGroups":47,"interventions":54,"overallOfficials":11,"centralContacts":59,"locations":65,"responsibleParty":166,"collaborators":11,"id":168,"slug":11,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":11,"eligibilityCriteria":173,"healthyVolunteers":169,"sex":174,"minAge":175,"maxAge":11,"enrollmentInfo":176,"targetDuration":11,"studyType":179,"phases":180,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"ModernaTX, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Dose-limiting Toxicity",null,"Up to 28 days",{"measure":14,"description":11,"timeFrame":15},"Number of Participants with Treatment-emergent Adverse Events (TEAEs)","Up to 15 months",[17,20,22,24,26,29,31,33,35,37,39],{"measure":18,"description":11,"timeFrame":19},"Maximum Plasma Concentration (Cmax)","Up to 1 year",{"measure":21,"description":11,"timeFrame":19},"Area Under the Concentration-time Curve (AUC)",{"measure":23,"description":11,"timeFrame":19},"Maximum Effect\u002FConcentration of the Expressed Protein (Emax)",{"measure":25,"description":11,"timeFrame":19},"Area Under the Effect Concentration (AUEC)",{"measure":27,"description":11,"timeFrame":28},"Overall Response Rate (ORR)","Up to 3 years",{"measure":30,"description":11,"timeFrame":28},"Duration of Response (DOR)",{"measure":32,"description":11,"timeFrame":28},"Progression-free Survival (PFS) based on International Myeloma Working Group (IMWG) Response Criteria",{"measure":34,"description":11,"timeFrame":28},"Overall Survival (OS)",{"measure":36,"description":11,"timeFrame":28},"Number of Participants with Minimal Residual Disease Negativity Status",{"measure":38,"description":11,"timeFrame":19},"Number of Participants with Antibodies to mRNA-2808 Derived Proteins",{"measure":40,"description":11,"timeFrame":19},"Number of Participants with Antibodies to mRNA-2808 Components",{"allocation":42,"interventionModel":43,"interventionModelDescription":11,"primaryPurpose":44,"observationalModel":11,"timePerspective":11,"maskingInfo":45},"NA","SINGLE_GROUP","TREATMENT",{"masking":46,"maskingDescription":11,"whoMasked":11},"NONE",[48],{"label":49,"type":50,"description":51,"interventionNames":52},"mRNA-2808","EXPERIMENTAL","Participants will receive mRNA-2808.",[53],"Drug: mRNA-2808",[55],{"type":56,"name":49,"description":57,"armGroupLabels":58,"otherNames":11},"DRUG","intravenous",[49],[60],{"name":61,"role":62,"phone":63,"phoneExt":11,"email":64},"Moderna WeCare Team","CONTACT","+1-866-663-3762","WeCareClinicalTrials@modernatx.com",[66,80,90,100,111,120,126,136,146,156],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":11},"University of Alabama at Birmingham Hospital","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":75,"coordinates":76},"Point",[77,78],-86.80249,33.52066,{"lat":78,"lon":77},{"facility":81,"status":68,"city":82,"state":83,"zip":84,"country":72,"countryCode":73,"cosmosGeoPoint":85,"geoPoint":89,"contacts":11},"UCSF","San Francisco","California","94143",{"type":75,"coordinates":86},[87,88],-122.41942,37.77493,{"lat":88,"lon":87},{"facility":91,"status":68,"city":92,"state":93,"zip":94,"country":72,"countryCode":73,"cosmosGeoPoint":95,"geoPoint":99,"contacts":11},"Emory University Hospital","Atlanta","Georgia","30322",{"type":75,"coordinates":96},[97,98],-84.38798,33.749,{"lat":98,"lon":97},{"facility":101,"status":102,"city":103,"state":104,"zip":105,"country":72,"countryCode":73,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"Mass General Brigham","NOT_YET_RECRUITING","Boston","Massachusetts","02114",{"type":75,"coordinates":107},[108,109],-71.05977,42.35843,{"lat":109,"lon":108},{"facility":112,"status":68,"city":113,"state":113,"zip":114,"country":72,"countryCode":73,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"Tisch Cancer Institute at Mount Sinai","New York","10029",{"type":75,"coordinates":116},[117,118],-74.00597,40.71427,{"lat":118,"lon":117},{"facility":121,"status":68,"city":113,"state":113,"zip":122,"country":72,"countryCode":73,"cosmosGeoPoint":123,"geoPoint":125,"contacts":11},"Memorial Sloan-Kettering Cancer Center","10065",{"type":75,"coordinates":124},[117,118],{"lat":118,"lon":117},{"facility":127,"status":68,"city":128,"state":129,"zip":130,"country":72,"countryCode":73,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Atrium Health Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":75,"coordinates":132},[133,134],-80.84313,35.22709,{"lat":134,"lon":133},{"facility":137,"status":68,"city":138,"state":139,"zip":140,"country":72,"countryCode":73,"cosmosGeoPoint":141,"geoPoint":145,"contacts":11},"Penn Medicine","Philadelphia","Pennsylvania","19104",{"type":75,"coordinates":142},[143,144],-75.16362,39.95238,{"lat":144,"lon":143},{"facility":147,"status":68,"city":148,"state":149,"zip":150,"country":72,"countryCode":73,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":75,"coordinates":152},[153,154],-86.78444,36.16589,{"lat":154,"lon":153},{"facility":157,"status":68,"city":158,"state":159,"zip":160,"country":72,"countryCode":73,"cosmosGeoPoint":161,"geoPoint":165,"contacts":11},"The Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":75,"coordinates":162},[163,164],-87.90647,43.0389,{"lat":164,"lon":163},{"type":167,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601908",false,"NCT07116616","A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 1\u002F2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","Key Inclusion Criteria:\n\n* RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody.\n* Measurable disease defined as at least 1 of the following:\n\n  * Serum M-protein ≥0.5 grams\u002Fdeciliter\n  * Urine M-protein ≥200 milligrams (mg)\u002F24-hour\n  * Involved free light chain (FLC) ≥100 mg\u002Fliter and an abnormal FLC ratio\n  * Plasmacytoma with a single diameter ≥2 centimeters\n  * Bone marrow plasma cells \\>30%\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement of myeloma.\n* Active plasma cell leukemia, defined as peripheral blood plasma cells ≥20%.\n* Radiotherapy or cytotoxic chemotherapy within 2 weeks prior to Day 1 (Baseline), except palliative radiotherapy of limited field is permissible within 2 weeks after discussion with the Sponsor medical monitor.\n* Antibody-based immunotherapy (monoclonal antibody, bispecific antibody, antibody drug conjugate) within 21 days prior to Day 1 (Baseline).\n* Proteasome inhibitor therapy or immunomodulatory agent within 14 days prior to Day 1 (Baseline).\n* Autologous hematopoietic cell transplant within 100 days prior to Day 1 (Baseline).\n* Allogeneic hematopoietic cell transplant within 180 days prior to Day 1 (Baseline).\n* Genetically modified adoptive autologous or allogeneic cellular therapy (for example, chimeric antigen receptor T cell, chimeric antigen receptor natural killer) within 12 weeks prior to Day 1 (Baseline).\n* Corticosteroid therapy ≥140 mg prednisone or equivalent cumulative dose within 14 days prior to Day 1 (Baseline).\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":177,"type":178},166,"ESTIMATED","INTERVENTIONAL",[181,182],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).",[185],"Relapsed or Refractory Multiple Myeloma",[187,188,189,190],"relapsed or refractory multiple myeloma","RRMM","multiple myeloma","MM","2026-06-25",{"date":193,"type":194},"2026-06-29","ACTUAL",{"date":196,"type":194},"2025-09-30",{"date":198,"type":178},"2032-06-17",{"name":5,"class":6},10]